The novel compound PBT434 prevents iron mediated neurodegeneration and alpha-synuclein toxicity in multiple models of Parkinson’s disease

The novel compound PBT434 prevents iron mediated neurodegeneration and alpha-synuclein toxicity in multiple models of Parkinson’s disease

Abstract Elevated iron in the SNpc may play a key role in Parkinson’s disease (PD) neurodegeneration since drug candidates with high iron affinity rescue PD animal models, and one candidate, deferirpone, has shown efficacy recently in a phase two clinical trial. However, strong iron chelators may pe...

Full description

Bibliographic Details
Main Authors: David I. Finkelstein, Jessica L. Billings, Paul A. Adlard, Scott Ayton, Amelia Sedjahtera, Colin L. Masters, Simon Wilkins, David M. Shackleford, Susan A. Charman, Wojciech Bal, Izabela A Zawisza, Ewa Kurowska, Andrew L. Gundlach, Sheri Ma, Ashley I. Bush, Dominic J. Hare, Philip A. Doble, Simon Crawford, Elisabeth CL. Gautier, Jack Parsons, Penny Huggins, Kevin J. Barnham, Robert A. Cherny
Format: Article
Language:English
Published: BMC 2017-06-01
Series:Acta Neuropathologica Communications
Subjects:
Synucleinopathy
Drug development
Chelation
Oxidative stress
Neuroprotection
Online Access:http://link.springer.com/article/10.1186/s40478-017-0456-2

Internet

http://link.springer.com/article/10.1186/s40478-017-0456-2

Similar Items